Improving Surgical Oncology
A medical device company with the goal to improve the surgical care for cancer patients.
SurGuide support surgeons in their aim to achieve complete tumor removal, which is the biggest challenge in cancer surgery. Incomplete tumor removal, negatively affects patient outcome and necessitates additional treatment1.
SurGuide’s technology addresses the problem that the information about the result of the operation becomes available only after several days. SurGuide’s technology will enable inspection of the resected tissue to determine if a tumor has been completely removed.
The result of this inspection is reported to the surgeon, while the patient is still in the operating room. The report shows at which locations the tumor has not been completely removed. Based on this critical feedback the surgeon can decide to perform an additional resection at the indicated locations.
In this way SurGuide’s technology will help to increase the rate of complete tumor resections.
Oral cavity cancer
SurGuide’s first focus is oral cavity cancer. Complete tumor removal in oral cavity cancer surgery requires resection of the tumor with a margin of more than 5mm of surrounding healthy tissue2. Our technology is not limited to oral cavity cancer. Other cancer types will follow after successful market introduction.
Head & Neck cancer is the seventh most common type of cancer in Europe. Head & Neck cancer includes o.a. Oral Cavity Cancer. More than 75%
Specimen-driven intraoperative assessment of resection margins should be standard of care for oral cancer patients
The Erasmus-university Medical Center recently published a review on the methods for intraoperative margin assessment. The review recommends the specimen-driven approach, which corresponds with the
Anand Manichand, takes on the role of Development and Commercial lead and thereby strengthens the team of SurGuide, a Rotterdam based MedTech start-up. In his